Is Haemonetics Corporation (HAE)’s Fuel Running Low? The Stock Reaches All Time High Today

March 14, 2018 - By Linda Rogers

Investors sentiment decreased to 1.28 in Q3 2017. Its down 0.42, from 1.7 in 2017Q2. It dropped, as 16 investors sold Haemonetics Corporation shares while 60 reduced holdings. 33 funds opened positions while 64 raised stakes. 52.55 million shares or 2.13% less from 53.69 million shares in 2017Q2 were reported.
Amer Capital Management Inc, New York-based fund reported 427,096 shares. Macquarie Gp Limited has invested 0.05% in Haemonetics Corporation (NYSE:HAE). Arrowstreet Cap Partnership holds 0.02% or 154,861 shares in its portfolio. Heartland invested in 0.48% or 165,494 shares. Comerica Bancorporation holds 0.02% or 64,687 shares in its portfolio. Btim invested in 0.21% or 294,791 shares. Teachers Retirement Of The State Of Kentucky holds 0.01% or 17,700 shares in its portfolio. 2,524 were reported by Employees Retirement Sys Of Ohio. Systematic Fincl Mngmt Limited Partnership holds 35,360 shares. Gemmer Asset Mngmt Ltd owns 105 shares. Reilly Finance Advisors Llc stated it has 0% in Haemonetics Corporation (NYSE:HAE). Vanguard Group invested 0.01% in Haemonetics Corporation (NYSE:HAE). Art Limited Liability Co reported 15,000 shares. Magnetar Financial Ltd Limited Liability Company invested in 0.01% or 6,270 shares. Tci Wealth holds 0% or 20 shares in its portfolio.

Since January 2, 2018, it had 0 buys, and 3 sales for $484,765 activity. Another trade for 114 shares valued at $8,234 was sold by Scanlan Jacqueline. $28,097 worth of Haemonetics Corporation (NYSE:HAE) was sold by Basil Michelle L on Tuesday, March 6.

The stock of Haemonetics Corporation (NYSE:HAE) reached all time high today, Mar, 14 and still has $80.58 target or 8.00 % above today’s $74.61 share price. This indicates more upside for the $3.99 billion company. This technical setup was reported by If the $80.58 PT is reached, the company will be worth $319.04M more.
Trading stocks at an all time highs is usually a winning strategy. An all time high points to a stock which has the most positive fundamentals ever. Even thought the pullback rate is high, if correct risk management is utilized, investors can trade very well such events.

The stock increased 0.27% or $0.2 during the last trading session, reaching $74.61. About 218,019 shares traded. Haemonetics Corporation (NYSE:HAE) has risen 45.56% since March 14, 2017 and is uptrending. It has outperformed by 28.86% the S&P500.

Analysts await Haemonetics Corporation (NYSE:HAE) to report earnings on May, 14. They expect $0.43 earnings per share, up 10.26 % or $0.04 from last year’s $0.39 per share. HAE’s profit will be $22.98M for 43.38 P/E if the $0.43 EPS becomes a reality. After $0.62 actual earnings per share reported by Haemonetics Corporation for the previous quarter, Wall Street now forecasts -30.65 % negative EPS growth.

Haemonetics Corporation (NYSE:HAE) Ratings Coverage

Among 10 analysts covering Haemonetics Corporation (NYSE:HAE), 4 have Buy rating, 0 Sell and 6 Hold. Therefore 40% are positive. Haemonetics Corporation had 27 analyst reports since July 29, 2015 according to SRatingsIntel. The rating was maintained by Benchmark with “Hold” on Thursday, November 5. The stock of Haemonetics Corporation (NYSE:HAE) earned “Market Outperform” rating by JMP Securities on Thursday, July 13. Barrington Research upgraded it to “Outperform” rating and $43 target in Tuesday, July 28 report. The company was maintained on Tuesday, August 2 by Jefferies. The firm has “Buy” rating by Jefferies given on Thursday, August 31. The firm earned “Mkt Perform” rating on Tuesday, February 7 by Barrington Research. The company was downgraded on Monday, November 23 by Raymond James. The firm has “Hold” rating given on Wednesday, November 8 by Craig Hallum. Benchmark maintained it with “Hold” rating and $34 target in Monday, November 7 report. The firm has “Buy” rating by Jefferies given on Monday, January 8.

Another recent and important Haemonetics Corporation (NYSE:HAE) news was published by which published an article titled: “Haemonetics (HAE) Up 4.2% Since Earnings Report: Can It Continue?” on March 08, 2018.

Haemonetics Corporation, a healthcare company, provides hematology products and solutions. The company has market cap of $3.99 billion. The firm operates through five divisions: North America Plasma; Americas Blood Center and Hospital; Europe, Middle East and Africa; Asia Pacific; and Japan. It currently has negative earnings. It offers plasma collection and storage products, including PCS brand plasma collection equipment and disposables, plasma collection containers, and intravenous solutions, as well as information technology platforms for plasma clients to manage their donors, operations, and supply chain; Multicomponent Collection System brand apheresis equipment to collect specific blood components integrated from the donor; Automated Cell Processor brand solution to automate the washing and freezing of red cell components; and whole blood collection and processing products.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.